Scientists track breast cancer Drug's journey through healthy women
NCT ID NCT04940026
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times
Summary
This early-stage study gave a single dose of a radioactive-labeled version of the experimental breast cancer drug amcenestrant to 6 healthy postmenopausal women. The goal was to track how the drug is absorbed, broken down, and eliminated from the body. The results will help guide future dosing and development of the drug for breast cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number 8260001
Nottingham, NG11 6JS, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amcenestrant (also known as SAR439859)
What this could lead to
This study helps researchers understand how amcenestrant moves through the body, which is important for future breast cancer treatment dosing.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. It only looks at drug processing, not whether the drug works against cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.